Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OC-1 (CD1a-CAR T) in R/R T-cell Acute Lymphoblastic Leukemia/Lymphoma
NCT05679895Phase 1Recruiting
- Sponsor
- OneChain Immunotherapeutics
- Start
- Jan 2023
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OC-1 in T-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL), sponsored by OneChain Immunotherapeutics. Primary endpoints: Number of adverse events grade III-IV at 1 year, Incidence of severe Cytokine release syndrome and Immune effector cell-associated neurotoxicity syndrome at 1 year and 5 more. Started Jan 2023; status: recruiting.
02
Drugs
OC-1
03
Conditions
T-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT05679895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05679895.